• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom beats earnings estimate by 12 cents in Q3

November 2, 2017 By Sarah Faulkner

DexcomShares in Dexcom (NSDQ:DXCM) soared today after the medical device maker topped expectations on Wall Street with its third quarter results.

The San Diego, Calif.-based company posted a net loss of -$2 million, or -2¢ per share, on sales of $184.6 million for the 3 months ended Sept. 30, for sales growth of 24% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -4¢, ahead of consensus on The Street, where analysts were looking for sales of $184.2 million.

“Our momentum this year carried through the third quarter, and we remain focused on driving the value proposition of DexCom’s real-time CGM to people with diabetes around the world,” president & CEO Kevin Sayer said in prepared remarks. “We are well positioned on a number of key initiatives, including the rollout of therapeutic CGM to the Medicare population and continued international expansion.”

Leerink analysts Danielle Antalffy and Rebecca Wang wrote in a note to investors that Dexcom’s continued growth will depend on its ability to capture the CGM market, especially given the latest regulatory win for Dexcom’s competitor, Abbott (NYSE:ABT).

“And given the meaningful competitive ‘noise’ in the market with the recent approval of ABT’s [MP] cheaper Libre, DXCM took the opportunity to guide FY2017 sales to the low end of management’s $710M-$740M guidance range,” the analysts wrote.

“Despite the Libre ‘noise,’ we did see what we believe are at the very least encouraging datapoints in the quarter: International strength continued, with y/y growth accelerating to over 80%. This sustained strength is encouraging as it is in these international markets where DXCM is currently competing head-to-head with Libre – and has been for 3 years – and is still managing to deliver strong growth (albeit off much smaller numbers).”

DXCM shares closed at $47.72 apiece today, up 6.4%.

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: abbott, DexCom Inc.

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS